Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. - Archive ouverte HAL Access content directly
Journal Articles Gut Year : 2020

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.

Frank Jülhing
  • Function : Author
Shen Li
  • Function : Author
Naoto Fujiwara
Ricard Masia
  • Function : Author
Mozhdeh Sojoodi
  • Function : Author
Gunisha Arora
  • Function : Author
Hiroshi Aikata
  • Function : Author
Atsushi Ono
Parissa Tabrizian
  • Function : Author
Myron Schwartz
  • Function : Author
Stephen J Polyak
  • Function : Author
Christian Schmidl
  • Function : Author
Christoph Bock
  • Function : Author
Kazuaki Chayama
  • Function : Author
Kenneth K Tanabe
  • Function : Author
Yujin Hoshida
Bryan C Fuchs
  • Function : Author

Abstract

Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related mortality with chronic viral hepatitis and non-alcoholic steatohepatitis (NASH) as major aetiologies. Treatment options for HCC are unsatisfactory and chemopreventive approaches are absent. Chronic hepatitis C (CHC) results in epigenetic alterations driving HCC risk and persisting following cure. Here, we aimed to investigate epigenetic modifications as targets for liver cancer chemoprevention.

Dates and versions

hal-02916776 , version 1 (17-08-2020)

Identifiers

Cite

Frank Jülhing, Nourdine Hamdane, Emilie Crouchet, Shen Li, Houssein El Saghire, et al.. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.. Gut, 2020, ⟨10.1136/gutjnl-2019-318918⟩. ⟨hal-02916776⟩
19 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More